trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['t-dxd', 'marker ']
 #esmo22 is her2 an agnostic marker or t-dxd an agnostic therapy ?
Medical Oncology at https://t.co/hCfxKt8kbP and https://t.co/YeizvuTGR3 Opinions are my own.